Sophie G. Kellaway,Sandeep Potluri,Peter Keane,Helen J. Blair,Luke Ames,Alice Worker,Paulynn S. Chin,Anetta Ptasinska,Polina K. Derevyanko,Assunta Adamo,Daniel J. L. Coleman,Naeem Khan,Salam A. Assi,Anja Krippner-Heidenreich,Manoj Raghavan,Peter N. Cockerill,Olaf Heidenreich,Constanze Bonifer

Abstract:Acute Myeloid Leukemia (AML) is caused by multiple mutations which dysregulate growth and differentiation of myeloid cells. Cells adopt different gene regulatory networks specific to individual mutations, maintaining a rapidly proliferating blast cell population with fatal consequences for the patient if not treated. The most common treatment option is still chemotherapy which targets such cells. However, patients harbour a population of quiescent leukemic stem cells (LSCs) which can emerge from quiescence to trigger relapse after therapy. The processes that allow such cells to re-grow remain unknown. Here, we examine the well characterised t(8;21) AML sub-type as a model to address this question. Using four primary AML samples and a novel t(8;21) patient-derived xenograft model, we show that t(8;21) LSCs aberrantly activate the VEGF and IL-5 signalling pathways. Both pathways operate within a regulatory circuit consisting of the driver oncoprotein RUNX1::ETO and an AP-1/GATA2 axis allowing LSCs to re-enter the cell cycle while preserving self-renewal capacity.

Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth